Secretagogue
A combined secretagogue preparation used in comparative preclinical research.
This blend pairs two compounds that researchers use to study how the body controls its own growth-hormone release. CJC-1295 imitates the natural 'release' signal (growth-hormone-releasing hormone), while Ipamorelin works through a separate pathway (the ghrelin receptor). They are studied together in preclinical models of how the pituitary gland secretes growth hormone.
Peptide blend
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Sequence
Tetrasubstituted GRF(1-29), C-terminal amide (D-Ala at position 2)
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Combines a GHRH-receptor (class B GPCR) agonist (CJC-1295 / Mod GRF 1-29) with a ghrelin / GHS-R1a (class A GPCR) agonist (Ipamorelin). The two components act on distinct receptor classes on pituitary somatotrophs; no single target applies.
Research Focus
Studied in growth-hormone-secretion physiology and somatotroph receptor pharmacology.
Lyophilized
-20°C
typically stable 24-36 months desiccated and protected from light.
Reconstituted
2-8°C for short-term use
-20°C/-80°C for longer storage.
Avoid freeze-thaw; aliquot; protect from light and moisture.
Raun K, et al. (1998). Eur J Endocrinol
Teichman SL, et al. (2006). J Clin Endocrinol Metab
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
